Array
(
[1553597490] => Array
(
[wordfence_processAttackData] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] =>
[args] => Array
(
)
)
)
)
[1553598752] => Array
(
[wordfence_hourly_cron] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1553600373] => Array
(
[wp_privacy_delete_old_export_files] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1553600881] => Array
(
[wpm_update_stats] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => hourly
[args] => Array
(
)
[interval] => 3600
)
)
)
[1553602352] => Array
(
[wordfence_daily_cron] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1553607126] => Array
(
[wp_update_themes] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
[wp_version_check] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
[wp_update_plugins] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1553607874] => Array
(
[wp_scheduled_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1553613473] => Array
(
[wp_session_garbage_collection] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => twicedaily
[args] => Array
(
)
[interval] => 43200
)
)
)
[1553616424] => Array
(
[akismet_scheduled_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1553619411] => Array
(
[yoast_tracking] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1553641250] => Array
(
[publish_future_post] => Array
(
[1f3d24059f96d9e259518bca8d2c4d45] => Array
(
[schedule] =>
[args] => Array
(
[0] => 399265
)
)
)
)
[1553641252] => Array
(
[publish_future_post] => Array
(
[f424dbe879bbeb64820a496b9b964c34] => Array
(
[schedule] =>
[args] => Array
(
[0] => 425172
)
)
)
)
[1553676571] => Array
(
[wp_scheduled_auto_draft_delete] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1553681711] => Array
(
[delete_expired_transients] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1553681752] => Array
(
[wpseo-reindex-links] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] => daily
[args] => Array
(
)
[interval] => 86400
)
)
)
[1554069658] => Array
(
[publish_future_post] => Array
(
[30870f619857112e7f5a94a898b1f874] => Array
(
[schedule] =>
[args] => Array
(
[0] => 428209
)
)
)
)
[1554130800] => Array
(
[wordfence_email_activity_report] => Array
(
[40cd750bba9870f18aada2478b24840a] => Array
(
[schedule] =>
[args] => Array
(
)
)
)
)
[1554674448] => Array
(
[publish_future_post] => Array
(
[ff60c73b1e4862a319c959dd8a390668] => Array
(
[schedule] =>
[args] => Array
(
[0] => 426546
)
)
)
)
[1560808829] => Array
(
[publish_future_post] => Array
(
[b5d3dc26a5d6e8c9ef68ff7210d9c108] => Array
(
[schedule] =>
[args] => Array
(
[0] => 413991
)
)
)
)
[1572217239] => Array
(
[publish_future_post] => Array
(
[e2d49b23925e3371aea8db1c72521461] => Array
(
[schedule] =>
[args] => Array
(
[0] => 421241
)
)
)
)
[1580169600] => Array
(
[publish_future_post] => Array
(
[2d492587fa52e9c78f7043ddf937b0a1] => Array
(
[schedule] =>
[args] => Array
(
[0] => 18611
)
)
[dea3edad73162f380bc9dc44fa3407bf] => Array
(
[schedule] =>
[args] => Array
(
[0] => 19670
)
)
[2caa9c58a241c4f77a6856802c1b43fb] => Array
(
[schedule] =>
[args] => Array
(
[0] => 20734
)
)
[307b37ba29b8cd716eafa809661756e3] => Array
(
[schedule] =>
[args] => Array
(
[0] => 22852
)
)
[365be9eba8e62abb0c0d4bfe013a2687] => Array
(
[schedule] =>
[args] => Array
(
[0] => 23918
)
)
[0e942b20ffb9550322105263ad82126f] => Array
(
[schedule] =>
[args] => Array
(
[0] => 24977
)
)
[661c5eb39689fe2133ff7986ac6628fb] => Array
(
[schedule] =>
[args] => Array
(
[0] => 26036
)
)
[75562b264e355915e4dea97042a28f7e] => Array
(
[schedule] =>
[args] => Array
(
[0] => 27095
)
)
[11cf4e8a6f842b0115881551a29c47f6] => Array
(
[schedule] =>
[args] => Array
(
[0] => 28154
)
)
[55a38aaca11da398c854cb29a7d4f5e6] => Array
(
[schedule] =>
[args] => Array
(
[0] => 30272
)
)
[f8cbc904676c235c7057ec965c01c023] => Array
(
[schedule] =>
[args] => Array
(
[0] => 32390
)
)
)
)
)
Etiquetas: 15 abril 2011, Asociación de Empresas Constructoras de Ámbito Nacional, Boletín Oficial del Estado, Carta, Comunidad de Madrid, David Taguas Coejo, Hospital del Henares, Hospital del sureste, Hospital del Tajo, Hospital Infanta Cristina, Hospital Infanta Leonor, Hospital Infanta Sofia, Javier Fernández-Lasquetty, Madrid, Plan General Contable, Plan Sectorial de Contabilidad, SEOPAN.
Etiquetas: 15 abril 2011, 15/04/2011, AEMPS, Agencia española de medicamentos y productos sanitarios, Agencia Europea de Medicamentos, Bisfosfonatos, Centro Autonómico de Farmacovigilancia, CHMP, Comité de Medicamentos de Uso Humano, EMA, Fractura atípica femoral, Fracturas atípicas de femur, Fracturas atípicas femorales, Madrid, medicamentos, Normativa interna, Nota informativa, Profesionales sanitarios, Riesgo, salud, Sanidad, seguridad, Situación clínica del paciente, Tratamiento, Uso humano.
Etiquetas: 15 abril 2011, 15/04/2011, AEMPS, Agencia española de medicamentos y productos sanitarios, Agencia Europea de Medicamentos, Agencias nacionales europeas, Alendronato, Biosfatos, CHMP, Clodronato, Comité de Medicamentos de Uso Humano, EMA, Etidronato, Fracturas atípicas de femur, Ibandronato, Medicamentos de uso humano, MUH, Pacientes en tratamiento con bisfosfonatos, Pamidronato, Profesionales sanitarios, Riesgos de fracturas atípicas de femur, Risedronato, salud, Sanidad, seguridad, Tiludronato, Tratamiento con bisfosfonatos, Tratamiento con el bisfosfonato, Tratamiento de la osteoporosis con bisfosfonatos, Zolendronato.
Utilizamos cookies propias y de terceros para recopilar información que ayuda a optimizar su visita. Las cookies no se utilizan para recoger información de carácter personal. Usted puede permitir su uso o rechazarlo, también puede cambiar su configuración siempre que lo desee. Al continuar con la navegación entendemos que se acepta nuestra política de cookies.
x.gif)